August 8, 2018
Quanterix’s ultra-sensitive Simoa assay has the potential to open new uses for the brain biomarker known as neurofilament light chain, including the possibility to detect early evidence of neurological diseases like multiple sclerosis (MS), Parkinson’s, and Alzheimer’s, and ably evaluate efforts to treat and prevent them, the company reports in a press release.
A hallmark of MS is the progressive degeneration of brain cells. As these cells are damaged, a protein called neurofilament light chain, or NfL, is released into cerebral spinal fluid and blood.
Studies have suggested that blood levels of NfL provide a reliable picture of MS activity, and could also be used to monitor disease progression, instead of magnetic resonance imaging scans of the brain. However, NfL’s use as a diagnostic marker for MS and other neurological disorders was limited due to lack of sensitive and reliable methods to assess it.
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
To receive MS news and information via e-mail, Please Click here
CLICK BOX to SUBSCRIBE to our MS Learning Channel on YouTube:
:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews
